<https://rdf.molmedb.upol.cz/reference/ref3684> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM491476>;
	<http://purl.org/ontology/bibo/pmid> "27347787"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM491477>,
		<https://identifiers.org/molmedb/MM491524>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.5b01871"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM491418>;
	<http://purl.org/dc/terms/bibliographicCitation> "Andersson V, Bergström F, Brånalt J, Grönberg G, Gustafsson D, Karlsson S, Polla M, Bergman J, Kihlberg J.: Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability. J Med Chem, Volume 59 (14), 2016"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1025679> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3684> .
<https://rdf.molmedb.upol.cz/interaction/int1025680> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3684> .
<https://rdf.molmedb.upol.cz/interaction/int1025756> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3684> .
<https://rdf.molmedb.upol.cz/interaction/int1025591> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3684> .